Published in Cancer Weekly, September 19th, 2000
"MAbs are currently approved for in vivo diagnosis and treatment of multiple diseases and have significant potential in the management of prostate cancer (Pca)," stated Neil H. Bander and colleagues from Weill Medical College of Cornell University, New York. "Prostascint, a MAb approved for Pca imaging, binds an intracellular epitope of PSMA and, as a result, does not bind to viable cells. Successful imaging of a given tumor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.